Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

Summary

The purpose of this phase I study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer. Biomarker testing to determine if patient is eligible for the trial must be completed prior to screening for the trial.

General Information

NCT#: NCT02857270
Study ID: 16419
Trial Phase: Phase I

Trial Sponsor: Eli Lilly
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Cetuximab, LY3214996, Abemaciclib, midazolam, Encorafenib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search